Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts
Federica Guffanti, M.F. Alvisi, Alessia Anastasia, Francesca Ricci, Michela Chiappa, Alba Llop‐Guevara, Violeta Serra, Robert Fruscio, Andrea Degasperi, Serena Nik‐Zainal, Maria Rosa Bani, Michela Lupia, Raffaella Giavazzi, Eliana Rulli, Giovanna Damia
Topics & Concepts
OlaparibRAD51Ovarian cancerCancer researchBiomarkerPARP inhibitorMedicineCisplatinCancerBiologySynthetic lethalityOncologyHomologous recombinationDNA repairInternal medicinePoly ADP ribose polymeraseChemotherapyGenePolymeraseGeneticsPARP inhibition in cancer therapyDNA Repair MechanismsOvarian cancer diagnosis and treatment